banner

Investors

At Acadia, we remain deeply committed to providing important new therapies to patients and delivering value for our stockholders. Our Investor Center is designed to provide you with convenient access to company information.

Recent News

04/05/21
- Conference call and webcast to be held today at 8:00 a.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Apr. 5, 2021-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Company has received a Complete Response Letter (CRL) from the U.S.
03/08/21
- Conference call and webcast to be held today at 5:00 p.m. Eastern Time SAN DIEGO --(BUSINESS WIRE)--Mar. 8, 2021-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Company received a notification from the U.S. Food and Drug Administration (FDA) on March 3, 2021 , stating that,
02/24/21
- Full year 2020 net sales grew to $441.8 million , a 30% increase over 2019 - Upcoming PDUFA action date of April 3, 2021 for supplemental New Drug Application for pimavanserin for the treatment of hallucinations and delusions associated with dementia-related psychosis SAN DIEGO --(BUSINESS